FDA Calendar

Biotech Stock Catalyst and FDA Calendar for your biotech stock investing. Use our tools on your road to profit in the stock market. Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA, Advisory Committee and Phase 2 & 3 trial data releases dates.

Refer to the Biotech Historical Catalyst Calendar for completed biotech stock catalysts.

The catalyst date is the LATEST expected date for the catalyst to occur by.  For example, if the catalyst date is 12/31/17, the event is expected to occur BY 12/31/17. It does NOT necessarily mean that the catalyst will occur ON this date. In most cases it will occur BEFORE.

Please refer to the "FDA Calendar Glossary" for a list of terms used in the FDA Decision Calendar.

LARGE CAP CATALYSTS - generally only Phase 3 catalysts noted in company presentations and/or earnings releases are shown.

PDUFA DATES - biosimilars and sNDA/sBLA filings and resubmissions are only noted if a PDUFA date has been released by the company. No official PDUFA date = No entry (e.g. Saxagliptin and dapagliflozin resubmission). Standard reviews for NDA/BLA filings use a 10 month estimate following filing acceptance for a NEW MOLECULAR ENTITY if no PDUFA date has been announced.

Pipeline data are current and updated daily! Click on the date for the source of the catalyst.


Financial data are delayed 15-35 minutes.

Subscribe HERE to ensure you receive your weekly FREE copy of the BioPharmCatalyst Biotech Stock Watch list and/or our daily option of Biotech Stock Price Movers and Pipeline Database updates


Showing 540 drugs
Ticker Price Drug Stage Catalyst
PLX
$0.71
-0  (-0.13%)
Pegunigalsidase alfa (PRX-102)
Fabry Disease
Phase 1/2
Phase 1/2 open-label extension clinical trial data to be presented November 24, 2017.
EARS
$0.85
+0.02  (+2.25%)
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3 4Q 2017 (likely late Nov)
Phase 3 HEALOS completion of enrollment announced June 5, 2017. Data due 4Q 2017 (likely late November).
AMGN
$169.96
+1.17  (+0.69%)
Repatha
Cardiovascular disease
PDUFA
Phase 3 cardiovascular outcomes study data released March 17, 2017 - endpoints met but down on expectations. PDUFA date under priority review December 2, 2017.
MYL
$37.21
+0.71  (+1.94%)
MYL-1401O - trastuzumab biosimilar
Trastuzumab biosimilar
PDUFA
PDUFA date originally set for September 3 extended by three months to December 3, 2017. Advisory Committee Meeting July 13, 2017 voted 16-0 recommending approval.
LOXO
$75.89
-1.51  (-1.96%)
Larotrectinib (LOXO-101)
Solid tumors that harbor a TRK fusion.
Phase 2 December 4-5, 2017
Announced 76% ORR at ASCO - June 3, 2017. Updated data due December 4-5, 2017 at AACR with NDA filing late 2017 or early 2018.
GSK
$35.02
-0.1  (-0.29%)
Dolutegravir + rilpivirine:
HIV
PDUFA priority review
Primary endpoint of non inferiority met - December 19, 2016. NDA filing announced June 5, 2017. Priority review requested - estimate PDUFA December 5, 2017 (6 month timeline) assuming priority review granted.
IMMU
$11.26
-0.32  (-2.77%)
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 3 December 5-9, 2017
Phase 3 enrollment commenced October 2017. BLA filing due between December 2017 and March 2018. Phase 2 data to be used for accelerated approval. Phase 2 updated data due at San Antonio Breast Cancer symposium (SABCS) December 5-9, 2017.
JNJ
$139.23
+1.3  (+0.94%)
Rilpivirine and Dolutegravir
HIV
PDUFA priority review
Primary endpoint of non inferiority met - December 19, 2016. NDA filing announced June 5, 2017. Priority review requested - estimate PDUFA December 5, 2017 (6 month timeline) assuming priority review granted.
NVO
$51.82
+0.39  (+0.75%)
Semaglutide
Type 2 diabetes
PDUFA December 5, 2017 (estimate only)
NDA filed December 5, 2016. PDUFA estimate December 5, 2017. Advisory Committee Meeting October 18, 2017 voted 16-0 in favor.
CASC
$4.12
+0.18  (+4.56%)
(Tucatinib ONT-380) and T-DM1
HER2+ Metastatic Breast Cancer (MBC)
Phase 1b December 5-9, 2017
Phase 1b updated data to be presented at SABCS December 5-9, 2017.
AFMD
$2.01
-0.04  (-2.2%)
AFM13 with Keytruda
Hodgkin Lymphoma - Cancer
Phase 1b
Phase 1b poster at ASH December 9, 2017.
AKTX
$4.57
+0.19  (+4.33%)
Coversin
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2 ASH 2017
Phase 2 interim data released April 24, 2017. Further update due at ASH December 9-12, 2017. Phase 3 program to commence 1Q 2018.
ARGX
$24.60
+0.02  (+0.08%)
ARGX-110
Relapsed/refractory cutaneous T-cell lymphoma (CTCL)
Phase 2 ASH 2017
Phase 2 interim data due by ASH 2017 with top-line data due by the end of 2018.
ARGX
$24.60
+0.02  (+0.08%)
ARGX-110
Acute myeloid leukemia (AML)
Phase 1/2 ASH 2017
Phase 1/2 interim data due by ASH 2017.
BLCM
$9.68
-0.05  (-0.52%)
BPX-501
Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer
Phase 1/2
Oral presentation at ASH December 9, 2017.
BLUE
$167.90
+2.5  (+1.51%)
bb2121
Relapsed/refractory multiple myeloma
Phase 1 ASH 2017
Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO June 5, 2017 - ORR 89%. Further data due at ASH 2017.
CBIO
$6.12
+0.02  (+0.32%)
CB 2679d/ ISU304
Hemophilia B
Phase 1/2
Phase 1/2 completion of dosing announced June 14, 2017 with interim data to be presented at ASH December 9, 2017. Top-line data due 1Q 2018.
CELG
$105.47
+2.31  (+2.24%)
JCAR017
Relapsed/refractory B cell non-Hodgkin lymphoma - cancer
Phase 1/2
Phase 1 updated data to be presented at ASH December 11, 2017.
CELG
$105.47
+2.31  (+2.24%)
CC-122
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM)
Phase 1/2 ASH 2017
Phase 1/2 trials ongoing. Data due at ASH 2017.
CLLS
$24.05
-0.24  (-0.99%)
UCART19 (PALL)
Acute lymphoblastic leukemia (ALL)
Phase 1
Phase 1 second interim data due at ASH 2017 (Pediatric 12/09/2017, adult 12/11/2017.
IMDZ
$4.18
+0  (+0%)
G100
Follicular non-Hodgkin Lymphoma - cancer
Phase 2 ASH 2017
Phase 2 data at ASCO 2017 (June 2, 2017). Also due at ASH 2017.
MGNX
$20.14
+0.44  (+2.23%)
Flotetuzumab
AML/MDS
Phase 1
Phase 1 interim data due at ASH December 9, 2017.
SGMO
$15.10
+0.4  (+2.72%)
SB-525 cDNA gene therapy
Hemophilia A
Phase 1/2 ASH 2017 - TBC
Possible late-breaker at ASH 2017.
STML
$14.45
+0.2  (+1.4%)
SL-401
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer
Phase 2 ASH 2017
Phase 2 enrollment completed - noted March 23, 2017. Update on patients enrolled in Stages 1 and 2 at EHA June 23, 2017. Top-line data from Stage 3 met primary endpoint - October 31, 2017 CR rate of 54% (7/13), with detailed data at ASH 2017.
XLRN
$37.44
+0  (+0%)
Sotatercept
Myelofibrosis
Phase 2
Phase 2 updated data at ASH December 9, 2017.
AGIO
$59.64
+1.05  (+1.79%)
AG-348
Pyruvate kinase deficiency
Phase 2
Phase 2 first data released at EHA meeting June 2016. Updated data due at EHA June 24, 2017 with further data due at ASH December 10, 2017. Pivotal trials to be initiated 1H 2018.
ATNM
$0.66
-0.01  (-2.22%)
Actimab-A
Acute Myeloid Leukemia (AML)
Phase 2
Phase 2 to initiated September 2016. Poster at ASH December 10, 2017 with top-line data due 1H 2018.
BLUE
$167.90
+2.5  (+1.51%)
LentiGlobin - HGB-206
Sickle disease
Phase 1/2
Update at ASH 2016. Further data due at ASH December 10, 2017.
CPRX
$3.22
+0.15  (+5.06%)
Firdapse
Lambert-Easton Myasthenic Syndrome (LEMS)
Phase 3 Early December 2017
Refusal to file letter reported on February 17, 2016. Data from second Phase 3 trial due early December 2017.
FBIO
$3.99
+0.02  (+0.5%)
CAEL‐101
AL amyloidosis
Phase 1/2 12/10/2017
Phase 1/2 data due at ASH December 10, 2017.
KDMN
$3.68
-0.01  (-0.28%)
KD025
Chronic graft-versus-host disease (cGVHD)
Phase 2
Phase 2 interim data presented July 11, 2017. ORR 71%. Updated data at ASH December 10, 2017.
KURA
$15.65
+0.2  (+1.29%)
Tipifarnib
Chronic myelomonocytic leukemia (CMML) - cancer
Phase 2
Phase 2 first dosing announced January 17, 2016. Preliminary data at ASH December 10, 2017.
KURA
$15.65
+0.2  (+1.29%)
Tipifarnib
Relapsed or refractory peripheral T-cell lymphoma
Phase 2
Phase 2 data presented at ICML conference on June 14, 2017 - 3/18 partial responses. Preliminary data at ASH December 10, 2017.
TGTX
$7.58
-0.12  (-1.63%)
TGR-1202
Relapsed or refractory lymphoma - cancer
Phase 1/2
Phase 1/2 initiated October 2016. Poster at ASH December 10, 2017.
AGIO
$59.64
+1.05  (+1.79%)
Ivosidenib
Frontline Acute myeloid leukemia (AML)
Phase 1
First data due from expansion trial at ASH December 11, 2017.
AGIO
$59.64
+1.05  (+1.79%)
Ivosidenib
R/R Acute Myeloid Leukemia (AML)
Phase 1
First data due from expansion trial at ASH December 11, 2017.
ALXN
$108.61
+0.12  (+0.11%)
ALXN1210
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1/2
Phase 3 data due 2Q 2018 (New Phase 1/2 data due at ASH December 11, 2017).
BPMC
$65.30
-1.74  (-2.59%)
BLU-285
Systemic mastocytosis (SM)
Phase 1/2
Updated data due at ASH December 11, 2017.
CELG
$105.47
+2.31  (+2.24%)
bb2121
Relapsed/refractory multiple myeloma
Phase 1
Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO June 5, 2017 - ORR 89%. Further data due at ASH December 11, 2017.
FATE
$4.40
+0.01  (+0.22%)
ProTmune - PROTECT
Acute graft-versus-host disease (GvHD) undergoing hematopoietic cell transplantation (HCT)
Phase 1/2
Phase 2 efficacy part of trial has been initiated - noted September 18, 2017. Phase 1 safety and efficacy data due at ASH December 11, 2017.
GBT
$38.20
-2.9  (-7.06%)
GBT440 HOPE-KIDS 1
Sickle cell disease - children age 6-17.
Phase 2a
Phase 2a initiated June 2016. Preliminary data released at European Hematology Association (EHA) - June 23, 2017. Noted July 10, 2017 that trial has been expanded to include a new single-dose cohort in children age 6 to 11. Updated data due at ASH December 11, 2017.
GERN
$1.94
+0.04  (+2.1%)
Imetelstat - IMerge Study
Myelodysplastic syndromes
Phase 2/3
Announced mid-January 2016 that Phase 2 dosing has been initiated. Internal reviews conducted September 2016 and April 2017, trial to continue as planned. Enrollment to be expanded 4Q 2017. Poster at ASH for patients in Part 1 of the trial - December 11, 2017.
GLYC
$12.40
-0.08  (-0.57%)
GMI-1271
Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer
Phase 1/2
Phase 1/2 updated data due at ASH - oral presentation December 11, 2017.
JUNO
$59.62
+0.56  (+0.94%)
JCAR017
r/r B cell non-Hodgkin lymphoma - cancer
Phase 1/2
Phase 1 updated data to be presented at ASH December 11, 2017.
TRIL
$10.30
+0.25  (+2.48%)
TTI-621
Solid tumors
Phase 1
Poster at ASH 2017.
STML
$14.45
+0.2  (+1.4%)
SL-401
High Risk Myeloproliferative Neoplasms
Phase 2 ASH 2017 - potentially
Phase 2 ongoing. ASH oral presentation - December 2016. Update due later in 2017.
STML
$14.45
+0.2  (+1.4%)
SL-401
Cancer- adult relapsed or refractory acute myeloid leukemia (AML)
Phase 2 ASH December 9-12, 2017
Phase 2 ongoing. ASH oral presentation - December 2016. Update due later at ASH 2017.
ACRS
$23.04
+0.22  (+0.96%)
A-101
Seborrheic keratosis (SK)
PDUFA
PDUFA date is December 24, 2017
AGRX
$4.88
+0.03  (+0.61%)
Twirla
Contraceptive patch
PDUFA
CRL issued 2013. Phase 3 top-line data released January 3, 2017 - poor data. NDA resubmitted with PDUFA date of December 26, 2017
CORI
$11.67
+0.72  (+6.57%)
Twirla
Contraceptive patch
PDUFA
Phase 3 top-line data released January 3, 2017 - poor data. NDA resubmitted by partner Agile Therapeutics with PDUFA date of December 26, 2017
VRX
$15.80
+0.23  (+1.44%)
Luminesse
Eye Brightener
PDUFA
PDUFA date December 27, 2017.
AEZS
$2.09
-0.01  (-0.46%)
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
PDUFA
CRL issued November 2014. Phase 3 data released January 4, 2017 - trial failed. NDA resubmitted with new PDUFA date of December 30, 2017.
ABBV
$95.19
+1.59  (+1.69%)
Risankizumab
Psoriatic Arthritis
Phase 2b YE 2017
Phase 2b data due 2017.
ADRO
$9.05
+0.3  (+3.42%)
CRS-207 with pembrolizumab
Mesothelioma - cancer
Phase 2 2H 2017
Phase 2 trial to be initiated 2Q 2017 with early data due 2H 2017.
ARDX
$6.16
+0.56  (+9.91%)
RDX7675
Hyperkalemia
Phase 2 4Q 2017
Onset of action trial data due 4Q 2017.
AST
$2.55
+0.05  (+2%)
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 1/2 YE 2017
Phase 1/2 six and nine-month data released January 24, 2017. 10 and 20 million cell cohort 6-month top-line data due January 2018. Cohort 2 12-month data due later in 2017.
ATNX
$18.11
+0.11  (+0.61%)
Oraxol
Metastatic breast cancer
Phase 3 YE 2017
Phase 3 interim data due 2017.
BIIB
$309.11
-0.35  (-0.12%)
BAN2401 (Aβ mAb)
Alzheimer’s disease
Phase 2 YE 2017
Phase 2 data due by the end of 2017.
BMY
$61.69
+0.89  (+1.45%)
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3
Phase 3 data due 2H 2017.
BMY
$61.69
+0.89  (+1.45%)
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3 2H 2017
Phase 3 data due 2H 2017.
BPTH
$0.30
+0  (+0.26%)
BP-1001
Acute myeloid leukemia (AML)
Phase 2 YE 2017
Phase 2 first patient enrolled November 2016. Interim analysis due by the end of 2017.
BTX
$2.62
+0.07  (+2.95%)
AST-OPC1 - SCiStar
Cervical spinal cord injury
Phase 1/2 YE 2017
Phase 1/2 six and nine-month data released January 24, 2017. 10 and 20m cell cohort 6-month top-line data due January 2018. Cohort 2 12-month data due later in 2017.
BYSI
$34.05
+0  (+0%)
Plinabulin (Trial 105)
Prevention of neutropenia
Phase 2/3 December 2017
Phase 2/3 enrollment announced April 25, 2017. Data from Phase 2 portion due December 2017. Interim data from Phase 3 portion due mid-2018.
CALA
$10.28
+0.15  (+1.48%)
CB-839 with paclitaxel
Triple negative breast cancer
Phase 2 4Q 2017
Phase 2 data due 4Q 2017.
CELG
$105.47
+2.31  (+2.24%)
REVLIMID - RELEVANCE
Newly Diagnosed Follicular Lymphoma
Phase 3 2H 2017
Phase 3 data due 2H 2017.
CELG
$105.47
+2.31  (+2.24%)
OTEZLA
Ulcerative Colitis
Phase 2 YE 2017
Phase 2 data due by the end of 2017.
CELG
$105.47
+2.31  (+2.24%)
GED-0301
Ulcerative Colitis
Phase 2 2H 2017
Phase 2 data due 2H 2017.
CEMP
$2.33
+0.03  (+1.08%)
Taksta - Fusidic acid
Refractory infections in bones and joints
Phase 2/3 YE 2017
Phase 2/3 data due by the end of 2017.
CLRB
$1.50
+0.01  (+1.01%)
CLR 131
Various lymphoma
Phase 2 2H 2017
Phase 2 trial initiation announced March 30, 2017. Initial data due 2H 2017.
CRMD
$0.53
+0.01  (+2.52%)
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 4Q 2017
Phase 3 data due 2H 2018 with interim analysis due 4Q 2017.
CYTK
$8.08
-3.02  (-27.26%)
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 3 4Q 2017
Phase 3 data are due 4Q 2017.
DCTH
$0.03
-0.01  (-15.7%)
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer
Phase 3 2H 2017
CRL issued September 13, 2013. New Phase 3 initiated February 2016. Ongoing as of November 2016. Interim safety analysis due 2H 2017.
EDGE
$9.61
+0.12  (+1.26%)
EG-1962
Improving patient outcomes following an aneurysmal subarachnoid hemorrhage (aSAH)
Phase 3 Late-2017
Phase 3 ongoing. Futility analysis late 2017. Interim top-line data due 1Q 2018. Full top-line data due late 2018.
EGLT
$0.99
-0.03  (-3.39%)
Egalet-002
Moderate to severe chronic pain
Phase 3 4Q 2017
Noted in August 2017 that NDA originally planned for 2019 has been delayed indefinitely. Noted in October 5, 2017 presentation that development has been "parked". However, noted further in on November 16, 2017 that trial will be completed 4Q 2017. Positive safety data also reported.
GALT
$3.08
+0.03  (+0.81%)
GR-MD-02
Non-alcoholic steatohepatitis (NASH) with cirrhosis
Phase 2b December 2017
Phase 2b top-line data due December 2017.
GILD
$72.26
+0.13  (+0.18%)
GS-9674
Primary biliary cholangitis
Phase 2 4Q 2017
Phase 2 interim analysis due 4Q 2017.
GSK
$35.02
-0.1  (-0.29%)
anti-SAP mAb
Amyloidosis
Phase 2b 4Q 2017
Phase 2b data likely due 4Q 2017.
GSK
$35.02
-0.1  (-0.29%)
GSK 166
Rheumatoid arthritis
Phase 2b 2H 2017
Phase 2b data due 2H 2017.
GSK
$35.02
-0.1  (-0.29%)
GSK 165
Osteoarthritis
Phase 2 2H 2017
Phase 2 data due 2H 2017.
IONS
$54.27
+0.53  (+0.98%)
IONIS-HTT Rx
Huntington's Disease
Phase 1/2 YE 2017
Phase 1/2 completion of enrollment noted June 22, 2017. Top-line data due around the end of 2017.
IRWD
$15.66
+0.01  (+0.06%)
IW-1973
Type 2 diabetic patients with hypertension
Phase 2a 4Q 2017
Phase 2a data due 4Q 2017.
IRWD
$15.66
+0.01  (+0.06%)
IW-1973
Type 2 diabetic patients with hypertension
Phase 2 4Q 2017
Phase 2a data due 4Q 2017.
KALA
$20.42
+0.82  (+4.18%)
INVELTYS
Phase 3 data due by the end of 2017.
Phase 3 YE 2017
Phase 3 data due by the end of 2017.
KALA
$20.42
+0.82  (+4.18%)
INVELTYS
Dry eye disease
Phase 3 YE 2017
Phase 3 data due by the end of 2017.
LLY
$84.09
+0.91  (+1.09%)
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3 YE 2017
Phase 3 ongoing. Data due 2017 (internal readout).
LLY
$84.09
+0.91  (+1.09%)
Alimta + Keytruda (MK-3475-189/KEYNOTE-189)
First-Line Non-Squamous Non-Small Cell Lung Cancer
Phase 3 YE 2017
Phase 3 data due late 2017.
MBVX
$0.67
+0.01  (+2.28%)
MVT-1075
Pancreatic, colon and lung cancers
Phase 1 YE 2017
Phase 1 interim data due by the end of 2017.
MBVX
$0.67
+0.01  (+2.28%)
MVT-5873
Pancreatic cancer
Phase 1 YE 2017
Phase 1 ongoing. Interim data reported November 2016 with further data due by the end of 2017.
MDGL
$43.14
-0.3  (-0.7%)
MGL-3196
Non-alcoholic steatohepatitis (NASH)
Phase 2 YE 2017
Phase 2 completion of enrollment announced August 1, 2017. Top-line data due end of 2017.
MRK
$54.68
+0.57  (+1.07%)
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 4Q 2017
Phase 3 data due 4Q 2017.
MRK
$54.68
+0.57  (+1.07%)
Ertugliflozin
Type 2 diabetes
PDUFA December 2017
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
MRSN
$18.00
+1.13  (+6.76%)
XMT1522
HER2 - breast cancer
Phase 1 YE 2017
Phase 1 safety data due around the end of 2017.
NKTR
$48.42
+2.02  (+4.35%)
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 4Q 2017
Phase 3 data due 4Q 2017.
NLNK
$8.88
-0.3  (-3.27%)
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 2 2H 2017
Phase 2 data due 2H 2017.
NVAX
$1.42
+0.06  (+4.04%)
NanoFlu vaccine
Influenza
Phase 1/2 4Q 2017
Phase 1/2 initiation announced September 19, 2017 with data due 4Q 2017.
NVS
$84.42
+1.2  (+1.44%)
LEE011: MONALEESA-3
Breast cancer - (post-menopausal)
Phase 3 4Q 2017
Phase 3 trial completion 4Q 2017.
OCRX
$1.75
+0.02  (+1.15%)
OCR-002
Cirrhosis
Phase 2a YE 2017
Phase 2a trial initiation announced June 1, 2017. Top-line data due by the end of 2017.
OGEN
$0.46
+0.02  (+4.23%)
AG013
Oral mucositis (OM)
Phase 2 YE 2017
Phase 2 dosing announced August 30, 2017. Preliminary data due by the end of 2017 with completion and full results due by the end of 2018.
PBYI
$104.85
+0.8  (+0.76%)
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 2 4Q 2017
Phase 2 additional data released December 8 2016 and April 4, 2017. Noted high rates of diarrhea. Additional data due 4Q 2017.
PFE
$35.68
+0.33  (+0.93%)
Xeljanz
Psoriatic arthritis
Phase 3 December 2017
PDUFA date December 2017. No exact date given. December 31, 2017 noted as last possible date using guidance of "December 31". Advisory Committee Meeting August 3, 2017 voted 10-1 in favor of recommending approval.
PFE
$35.68
+0.33  (+0.93%)
Ertugliflozin
Type 2 diabetes
Phase 3 December 2017
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
PFE
$35.68
+0.33  (+0.93%)
BOSULIF
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
PDUFA priority review December 2017
Phase 3 trial met primary endpoint - December 2016. PDUFA date under priority review for sNDA filing December 2017. Exact date not provided.
PHMMF
$2.73
-0.06  (-2.16%)
Zepsyre(PM1183)
Platinum resistant ovarian cancer
Phase 3 YE 2017
Phase 3 data readout due year end 2017.
PTI
$2.00
+0.07  (+3.62%)
PTI-428
Cystic fibrosis
Phase 2 4Q 2017
Phase 2 28-day data due 4Q 2017.
RARX
$14.17
+0.13  (+0.92%)
RA101495
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2 YE 2017
Phase 2 data due YE 2017.
RDUS
$27.33
-0.09  (-0.33%)
Elacestrant
Vasomotor symptoms
Phase 2b YE 2017
Development update due by end of 2017.
REGN
$386.45
+1.23  (+0.31%)
EYLEA + nesvacumab
Diabetic macular edema (DME)
Phase 2 YE 2017
Phase 2 enrollment completed 4Q 2016. Data due by end of 2017.
REGN
$386.45
+1.23  (+0.31%)
EYLEA + nesvacumab
AMD - age-related macular degeneration
Phase 2 YE 2017
Phase 2 data due by end of 2017.
RETA
$24.92
+0.49  (+2%)
Omaveloxolone - REVEAL
Metastatic melanoma
Phase 1/2 2H 2017
Phase 1b portion of trial due 2H 2017
RGLS
$0.90
-0  (-0.39%)
RG-012
Renal biopsy study in Alport patients
Phase 1/2 YE 2017
Phase 1/2 data due year end 2017.
RGNX
$28.85
+1.05  (+3.77%)
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
Phase 1/2 YE 2017
Phase 1/2 dosing initiated - March 8, 2017. Interim data due by the end of 2017.
RNN
$2.13
+0.01  (+0.71%)
Supinoxin
Triple negative breast cancer
Phase 2a 4Q 2017
Phase 2a initial data due 4Q 2017.
RNN
$2.13
+0.01  (+0.71%)
RX-3117
Relapsed and refractory pancreatic cancer
Phase 2 4Q 2017
Updated Phase 2a data presented at ASCO GI January 20, 2017. Further data due 4Q 2017.
RNN
$2.13
+0.01  (+0.71%)
Archexin
Renal cell carcinoma (RCC) - cancer
Phase 2a 4Q 2017
Phase 2a second stage enrollment commenced February 2016. Initial data due 4Q 2017.
RVNC
$24.65
+0.05  (+0.2%)
RT002 - SAKURA 2
Moderate to severe glabellar (frown) lines
Phase 2 4Q 2017
Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RVNC
$24.65
+0.05  (+0.2%)
RT002
Plantar fasciitis
Phase 2 YE 2017
Phase 2 completion of enrollment noted October 18, 2017. Data due towards the end of 2017.
RVNC
$24.65
+0.05  (+0.2%)
RT002 - SAKURA 1
Moderate to severe glabellar (frown) lines
Phase 3 4Q 2017
Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RXII
$0.62
-0  (-0.09%)
RXI-109-1402
Connective tissue growth factor (CTGF)
Phase 2 YE 2017
Phase 2 final readout due 2H 2017.
RXII
$0.62
-0  (-0.09%)
Samcyprone - RXI-SCP-1502
Cutaneous warts
Phase 2 YE 2017
Phase 2 enrollment completed - noted September 6, 2017. Data read outs due before the end of 2017.
SAGE
$87.15
+3.26  (+3.88%)
SAGE-217
Major Depressive Disorder (MDD)
Phase 2 4Q 2017
Phase 2 initiation announced December 19, 2016. Part B data due 4Q 2017.
SAGE
$87.15
+3.26  (+3.88%)
SAGE-217
Essential tremor
Phase 2 4Q 2017
Announced that screening has opened for Phase 2a trial - December 13, 2016. Data due 4Q 2017.
TCON
$2.60
-0.05  (-1.89%)
TRC105
Soft tissue sarcomas
Phase 2 2H 2017
Phase 2 data due 2H 2017.
VKTX
$2.82
+0.05  (+1.8%)
VK5211
Acute Hip Fracture
Phase 2 4Q 2017
Phase 2 completion of enrollment announced July 12, 2017 with data due 4Q 2017.
VNDA
$13.10
+0.05  (+0.38%)
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 2 4Q 2017
Phase 2 data due in 4Q 2017.
VRX
$15.80
+0.23  (+1.44%)
SAN-300
Rheumatoid Arthritis
Phase 2 2H 2017 (est. only)
Phase 2 data due 1H 2017 according to latest company guidance. Timeline has passed.
XBIT
$4.17
+0.04  (+0.96%)
Xilonix
Pyoderma Gangrenosum
Phase 2 2017 est only
Noted November 2016 that Phase 2 trial has been completed and data is being finalized. Noted mid-March 2017 that data will be available soon. No definitive timeline given. Assume some time in 2017.
XENT
$29.20
+0.4  (+1.38%)
RESOLVE steroid-releasing implant
Recurrent sinus obstruction
PDUFA
PDUFA January 7, 2018.
EIGR
$11.00
+0.3  (+2.8%)
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2
Phase 2 initiated July 2016. Enrollment completion announced May 15, 2017 with data due 1Q 2018 at JPM Conference - January 8-11, 2018.
BOLD
$28.46
+1  (+3.64%)
AT132 - ASPIRO
X-Linked Myotubular Myopathy
Phase 1/2 Early January 2018
Phase 1/2 dosing has commenced - noted September 21, 2017 with preliminary data due early January 2018.
LLY
$84.09
+0.91  (+1.09%)
Abemaciclib - MONARCH 1 and 2
Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer
PDUFA priority review
Phase 3 data released March 20, 2017 - PFS primary endpoint met. Noted July 10, 2017 PDUFA under priority review. No exact data released. Assume 6-month review rendering a PDUFA date on or around January 10, 2018.
LPCN
$3.57
+0  (+0%)
LPCN 1021
Men with low testosterone (Low T)
PDUFA Adcom January 10
CRL issued June 2016. NDA resubmitted with PDUFA orginally scheduled for February 8, 2017 but delayed until May 8, 2017 due to submission of additional data. Advisory Committee meeting January 10, 2018.
ONCE
$72.24
-0.48  (-0.67%)
Luxturna (voretigene neparvovec)
Inherited retinal dystrophies
PDUFA priority review
PDUFA date January 12, 2018 under priority review. Advisory Committee Meeting October 12, 2017 voted 16-0 in favor of recommending approval.
AXSM
$4.71
+0.11  (+2.39%)
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 Late December 2017/early January 2018
Initiated July 2015. Interim efficacy analysis due late December 2017 or early January 2018.
AXSM
$4.71
+0.11  (+2.39%)
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 Late December 2017/early January 2018
Phase 3 commenced March 2016. Interim efficacy analysis due late December 2017 or early January 2018.
BLRX
$1.04
-0.01  (-0.96%)
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Phase 2 January 18-20, 2018
Phase 2 initiated September 2016. Partial data to be presented at ASCO 2018 Gastrointestinal Cancers Symposium, January 18-20, 2018. Full data due 2H 2018.
SGYP
$1.94
+0.04  (+1.84%)
Trulance (plecanatide)
Constipation-predominant irritable bowel syndrome (IBS-C)
PDUFA
Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. PDUFA date January 24, 2018.
AAAP
$81.20
+0.04  (+0.04%)
Lutathera
Inoperable progressive midgut NETs
PDUFA
CRL issued December 21, 2016. NDA to be resubmission announced July 27, 2017 with new PDUFA date January 26, 2018.
ARDM
$3.64
+0.1  (+2.82%)
Linhaliq (Pulmaquin)
Non-cystic fibrosis bronchiectasis (non-CF BE).
PDUFA priority review
PDUFA date under priority review January 26, 2018. Phase 3 data released December 1, 2016. One of two trials met primary endpoint.
SCMP
$10.35
+0  (+0%)
Lubiprostone
Pediatric functional constipation
PDUFA
PDUFA date for sNDA under priority review January 28, 2018.
AXON
$5.51
+0.13  (+2.41%)
Intepirdine
Gait and Balance Impairments in Dementia
Phase 2 January 2018
Phase 2 data due January 2018.
AXON
$5.51
+0.13  (+2.41%)
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
Phase 2b January 2018
Phase 2b data due January 2018.
AXON
$5.51
+0.13  (+2.41%)
Nelotanserin
Visual hallucinations in subjects with Lewy body dementia
Phase 2 January 2018
Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Top-line data due January 2018.
KDMN
$3.68
-0.01  (-0.28%)
KD025
Idiopathic pulmonary fibrosis (IPF)
Phase 2 January 2018
Phase 2 data due January 2018.
PFE
$35.68
+0.33  (+0.93%)
Talazoparib
BRCA-mutated breast cancer
Phase 3 January 2018
Phase 3 data due January 2018.
XLRN
$37.44
+0  (+0%)
ACE-083
Facioscapulohumeral muscular dystrophy
Phase 2 January 2018
Phase 2 dosing initiation announced December 22, 2016. Initial data due January 2018.
AMAG
$13.63
-0.47  (-3.37%)
Feraheme
Adults with iron deficiency anemia (IDA)
PDUFA
PDUFA date February 2, 2018 for sNDA filing.
PTLA
$51.08
+1.57  (+3.17%)
Andexanet alfa
Factor Xa inhibitor reversal agent
PDUFA
CRL August 17 2016. New PDUFA date February 2, 2018.
AMGN
$169.96
+1.17  (+0.69%)
XGEVA
Multiple Myeloma
PDUFA
sBLA filing announced April 4, 2017. Acceptance of filing announced June 19, 2017 - PDUFA February 3, 2018.
GILD
$72.26
+0.13  (+0.18%)
Bictegravir/F/TAF
HIV
PDUFA priority review
PDUFA date under priority review February 12, 2018.
AMAG
$13.63
-0.47  (-3.37%)
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
PDUFA
sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review.
ATRS
$1.84
+0.02  (+1.09%)
Makena - auto injector
Preterm birth
PDUFA
sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review
PCRX
$41.50
-0.7  (-1.66%)
EXPAREL
Single-dose injection femoral nerve block for total knee arthroplasty surgery
PDUFA Adcom 2/14/18; PDUFA 4/6/18
Phase 3 data released July 25, 2017. Upper extremity met primary endpoint, lower extremity trial missed endpoint. PDUFA date for sNDA filing set for April 6, 2018. Advisory Committee Meeting February 14-15, 2018.
EXEL
$26.06
+0.41  (+1.59%)
Cabozantinib - CABOSUN
First-Line RCC - cancer
PDUFA priority review
Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018.
KURA
$15.65
+0.2  (+1.29%)
Tipifarnib
Head and neck squamous cell carcinomas (HNSCC)
Phase 2 February 15-17, 2018
Presentation of updated data due February 15-17, 2018 at Multidisciplinary Head and Neck Cancers Symposium.
APRI
$1.61
-0.01  (-0.93%)
Vitaros
Erectile dysfunction
PDUFA
PDUFA date for NDA resubmission February 17, 2018.
KMPH
$3.80
-0.05  (-1.3%)
KP201/APAP
Acute pain.
PDUFA
PDUFA date February 23, 2018 - CRL issued June 13, 2016.
AERI
$61.73
+2.02  (+3.39%)
Rhopressa
Glaucoma
PDUFA
PDUFA date February 28, 2018. Advisory Committee meeting October 13, 2017 voted 9-1 in favor that efficacy outweighs safety risks,
AZN
$33.87
+0.49  (+1.47%)
Lynparza
Breast cancer
PDUFA priority review 1Q 2018
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). PDUFA date for sBLA under priority review 1Q 2018.
LJPC
$34.38
+0.19  (+0.55%)
LJPC-501
Hypotension
PDUFA priority review
Phase 3 data released February 27, 2016 - primary endpoint hit. Data published May 21, 2017 confirmed primary endpoint was met but with lack of mortality improvement. PDUFA date under priority review February 28, 2018. No Advisory Committee Meeting planned.
MDGL
$43.14
-0.3  (-0.7%)
MGL-3196
Heterozygous familial hypercholesterolemia (HeFH)
Phase 2 Early 2018
Phase 2 top-line data due early 2018.
MRK
$54.68
+0.57  (+1.07%)
Lynparza
Breast cancer
PDUFA priority review 1Q 2018
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). PDUFA date for sBLA under priority review 1Q 2018.
MRNS
$6.39
+0.08  (+1.26%)
Ganaxolone
Postpartum depression
Phase 2 Early 2018
Phase 2 data due early 2018.
ONTX
$1.69
-0.01  (-0.72%)
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)
Phase 3 Late 2017/early 2018
Phase 3 enrolling. Interim analysis due late 2017 or early 2018. Top-line data due 2H 2018.
SRNE
$2.33
-0.08  (-3.13%)
ZTlido (lidocaine patch 1.8%)
Pain associated with post-herpetic neuralgia (PHN)
PDUFA
PDUFA date for NDA resubmission February 28, 2017.
VRTX
$145.16
+0.52  (+0.35%)
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
PDUFA priority review
Phase 3 data released March 28, 2017 - primary endpoint met. PDUFA date under priority review February 28, 2017.
OTIC
$5.40
-0.05  (-0.92%)
OTIPRIO
Acute otitis externa
PDUFA
Phase 3 trial met primary endpoint - January 5, 2017. PDUFA date for sNDA filing March 2, 2018.
BMY
$61.69
+0.89  (+1.45%)
Opdivo - 4 week applications
PDUFA
PDUFA date March 5, 2018 for sBLA filings across all approved indications.
PFE
$35.68
+0.33  (+0.93%)
Xeljanz
Ulcerative colitis
PDUFA
sNDA acceptance announced July 13, 2017. Exact PDUFA date not released by company. BioPharmCatalyst estimate March 13 using 8-month timeline.
BIIB
$309.11
-0.35  (-0.12%)
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2b Early-2018
Phase 2b data due early 2018.
ABIO
$1.45
-0.05  (-3.34%)
Gencaro - GENETIC-AF trial
Chronic Heart Failure
Phase 2b 1Q 2018
Phase 2b completion of enrollment announced August 16, 2017 - top-line data due late 1Q 2018.
ACOR
$20.00
+0.5  (+2.56%)
Tozadenant
Parkinson’s disease (PD)
Phase 3 1Q 2018
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Phase 3 data due 1Q 2018. However, company noted November 20, 2017 that program will be discontinued.
AIMT
$35.26
+0.4  (+1.14%)
AR101 PALISADE
Peanut Allergy
Phase 3 1Q 2018
Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due 1Q 2018.
ALT
$2.08
+0.02  (+0.97%)
NasoVAX
Flu vaccine
Phase 1/2 1Q 2018
Phase 2 initial data due 1Q 2018.
ANAB
$77.54
+2.27  (+3.02%)
ANB020
Severe adult peanut allergy
Phase 2a 1Q 2018
Phase 2a data due 1Q 2018.
ANTH
$2.14
+0.08  (+3.88%)
Sollpura - RESULT
Exocrine pancreatic insufficiency
Phase 3 1Q 2018
Phase 3 data due end 1Q 2018.
ARGX
$24.60
+0.02  (+0.08%)
ARGX-113
Myasthenia gravis (MG)
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
ARNA
$27.29
+0.6  (+2.24%)
APD371
Pain associated with Crohn's disease
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
ARNA
$27.29
+0.6  (+2.24%)
Etrasimod
Ulcerative colitis
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
AVEO
$3.04
-0.06  (-1.78%)
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 3 1Q 2018
Phase 3 completion of enrollment noted June 20, 2017. Futility analysis released October 6, 2017 - trial to continue as planned. Top-line data due 1Q 2018.
AXON
$5.51
+0.13  (+2.41%)
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
BMY
$61.69
+0.89  (+1.45%)
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 Late 2017/Early 2018
Phase 3 interim data due end of 2017 or early in 2018.
CDTX
$8.05
+0.1  (+1.25%)
Rezafungin (CD101) IV - STRIVE
Candidemia
Phase 2 1Q 2018
Phase 2 initiated June 2016. Data due 1Q 2018.
CELG
$105.47
+2.31  (+2.24%)
REVLIMID - AUGMENT NHL-007
Relapsed or Refractory Follicular Lymphoma
Phase 3 1Q 2018
Phase 3 enrolling. Data due 1Q 2018.
CLBS
$3.30
+0  (+0%)
CLBS03
Type 1 diabetes
Phase 2 1Q 2018
Phase 2 top-line data due 1Q 2018.
CLSD
$6.94
-0.06  (-0.86%)
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis
Phase 3 1Q 2018
Phase 3 completion of enrollment noted August 7, 2017 with preliminary data due 1Q 2018.
CORT
$17.51
+0.42  (+2.45%)
CORT125134
Cushing’s syndrome
Phase 2 1Q 2018
Phase 2 trial initiated 2Q 2016. Data due 1Q 2018.
CYTK
$8.08
-3.02  (-27.26%)
CK-2127107
Spinal muscular atrophy (SMA)
Phase 2
Phase 2 initiated January 2016. Baseline data from first cohort released June 5, 2017. Cohort 2 enrollment to be completed in 2017. Data due 1Q 2018.
DERM
$24.06
+0.06  (+0.22%)
Olumacostat glasaretil (DRM01)
Acne
Phase 3 1Q 2018
Phase 3 completion of enrollment announced October 5, 2017. Data are due 1Q 2018.
EARS
$0.85
+0.02  (+2.25%)
Keyzilen (AM-101) - TACTT3
Acute inner ear tinnitus
Phase 3
Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line data 1Q 2018.
ESPR
$56.67
+3.5  (+6.59%)
Bempedoic Acid - 1002-039
Hypercholesterolemia
Phase 2
Phase 2 initiation announced July 26, 2017 - data due 1Q 2018.
EYEG
$1.10
+0.01  (+0.91%)
EGP-437
Ocular inflammation and pain post cataract surgery
Phase 2b 1Q 2018.
Phase 1/2 top-line data released July 2016. Further data released December 5, 2016. Phase 2b commencement of enrollment announced August 1, 2017. Data due 1Q 2018.
FGEN
$48.55
+1  (+2.1%)
Pamrevlumab (FG-3019)
Pancreatic cancer
Phase 2
Phase 2 ongoing. Data due late 2017 or 1Q 2018.
GALE
$0.30
+0  (+0.63%)
NeuVax in combination with Herceptin
Breast cancer - 1+/2+
Phase 2b 1Q 2018
Phase 2b completion of enrollment announced September 28, 2017 - with interim efficacy analysis due 1Q 2018.
GERN
$1.94
+0.04  (+2.1%)
Imetelstat - IMbarkStudy
Myelofibrosis
Phase 2
Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Further internal data review due 1Q 2018.
GILD
$72.26
+0.13  (+0.18%)
GS-9674
Primary sclerosing cholangitis
Phase 2 1Q 2018
Phase 2 primary endpoint analysis due 1Q 2018.
GILD
$72.26
+0.13  (+0.18%)
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 2 1Q 2018
Phase 2 trial to be completed 1Q 2018.
GILD
$72.26
+0.13  (+0.18%)
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 2 1Q 2018
Phase 2 interim analysis due 1Q 2018.
GLMD
$8.05
-0.08  (-1.04%)
Aramchol - ARRIVE
HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD)
Phase 2 1Q 2018
Phase 2 top-line data due 1Q 2018.
GSK
$35.02
-0.1  (-0.29%)
Dolutegravir + lamivudine (GEMINI 1)
HIV
Phase 3
Phase 3 trial commenced August 2016. Data likely due 1Q 2018.
GTHX
$20.27
+0.3  (+1.5%)
Trilaciclib
First-line small-cell lung cancer
Phase 2 1Q 2018
Phase 2a top-line data due 1Q 2018.
GWPH
$127.46
+12.69  (+11.05%)
GWP42006 (CBDV)
Epilepsy
Phase 2
Phase 2 initiated May 2015. Data due late 2017 or early 2018.
IMRN
$5.33
-0.13  (-2.38%)
IMM-124E
Nonalcoholic steatohepatitis (NASH)
Phase 2 1Q 2018
Phase 2 interim analysis July 10, 2017 showed no statistical difference with placebo. Top-line data due 1Q 2018.
MBIO
$9.28
-0.15  (-1.6%)
MB-102
Acute myeloid leukemia
Phase 1
Phase 1 data due early 2018.
MBIO
$9.28
-0.15  (-1.6%)
MB-101
Glioblastoma
Phase 1
Phase 1 data due early 2018.
MCRB
$9.36
-0.03  (-0.27%)
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 1b
Phase 1b initiated July 2016. Data due early 2018.
MESO
$4.95
-0.1  (-1.99%)
MPC-150-IM - Class IV
Chronic heart failure (CHF)
Phase 2b
Phase 2b data due 1Q 2018.
MESO
$4.95
-0.1  (-1.99%)
MSC-100-IV
acute graft versus host disease (aGVHD) in children
Phase 3 1Q 2018
Phase 3 enrollment to be completed 4Q 2017. Data due 1Q 2018.
MRTX
$17.85
-0.4  (-2.2%)
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
MYOK
$36.65
-0.2  (-0.55%)
MYK-461 - PIONEER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 1Q 2018
Phase 2 top-line data released August 7, 2017 - primary endpoint met. Data from low dose cohort due 1Q 2018. Phase 3 EXPLORER-HCM trial to be initiated 2Q 2018.
OBSV
$10.65
-0.1  (-0.94%)
OBE001 - IMPLANT2
IVF
Phase 2 1Q 2018
Phase 2 trial did not meet primary endpoint in 2016. Phase 3 completion of patient recruitment announced September 6, 2017. Data due 1Q 2018.
OHRP
$0.72
+0.03  (+3.61%)
OHR-102 (MAKO)
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase 3
Phase 3 data due early 2018.
PFE
$35.68
+0.33  (+0.93%)
Tanezumab
Chronic low back pain
Phase 3
Phase 3 ongoing. Estimate data due late 2017 or early 2018 using clinicaltrials.gov data.
PFE
$35.68
+0.33  (+0.93%)
Tanezumab
Osteoarthritis
Phase 3
Phase 3 ongoing. Estimate data late 2017 or early 2018 using clinicaltrials.gov data.
PLX
$0.71
-0  (-0.13%)
OPRX-106
Ulcerative Colitis
Phase 2 Early 2018.
Phase 2 trial initiation announced November 30, 2016. Data due early 2018.
PTGX
$19.03
+0.47  (+2.53%)
PTG-100
Ulcerative colitis
Phase 2b
Phase 2b initiation announced January 17, 2017. Interim futility analysis early 2018 with top-line data due 2018.
RARE
$47.83
-0.01  (-0.04%)
DTX301
Ornithine Transcarbamylase (OTC) Deficiency
Phase 1/2 Early 2018
Phase 1/2 first cohort of three patients have completed patient dosing with initial data due early 2018.
REGN
$386.45
+1.23  (+0.31%)
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3
Phase 3 data due 1Q 2018.
RETA
$24.92
+0.49  (+2%)
Bardoxolone methyl - LARIAT
Pulmonary hypertension due to interstitial lung disease - PH-ILD
Phase 2 1Q 2018
Phase 2 enrollment commenced January 2017. Data due 1Q 2018.
RETA
$24.92
+0.49  (+2%)
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
Phase 2 1Q 2018
Phase 2 initial data due 1Q 2018.
RXII
$0.62
-0  (-0.09%)
RXI-109-1501
Retinal scarring
Phase 1/2
Phase 2 completion of enrollment announced June 21, 2017. Data due early 2018.
SAGE
$87.15
+3.26  (+3.88%)
SAGE-217
Postpartum depression (PPD)
Phase 2 1Q 2018
Phase 2 initiation announced December 4Q 2016. Data due 1Q 2018.
SMMT
$11.21
-0.58  (-4.92%)
Ezutromid
Duchenne muscular dystrophy
Phase 2 1Q 2018
Phase 2 completion of initial dosing announced November 20, 2017. 24-week data due 1Q 2018.
SNY
$44.93
+0.61  (+1.37%)
SAR439684 (PD-1)
Cutaneous squamous cell carcinoma
Phase 2
Phase 2 data due 1Q 2018.
SNY
$44.93
+0.61  (+1.37%)
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3
Phase 3 data due 1Q 2018.
SPHS
$2.05
+0.01  (+0.25%)
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 2 Late-1Q 2018
Phase 2b initial biopsy data due late 1Q 2018.
SPPI
$20.03
+0.91  (+4.75%)
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Phase 3 1Q 2018
Phase 3 completion of enrollment announced August 1, 2017 with top-line data due 1Q 2018.
TCON
$2.60
-0.05  (-1.89%)
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 Early 2018
Phase 2 initiated Dec 2014. Completion of enrollment announced September 7, 2017. Top-line PFS data due early 2018.
TTPH
$6.58
+0.25  (+3.94%)
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
Phase 3 1Q 2018
Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial initiation announced January 17, 2016. Completion of enrollment announced September 11, 2017. Data due 1Q 2018.
VBLT
$7.00
+0.05  (+0.71%)
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 3 1Q 2018
Phase 3 completion of enrollment announced January 6, 2017. Top-line data due 1Q 2018.
VICL
$1.97
-0.01  (-0.51%)
ASP0113 Vaccine
Hematopoietic cell transplant recipients
Phase 3 1Q 2018
Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018.
VTVT
$5.32
+0.1  (+1.91%)
Azeliragon - STEADFAST
Mild Alzheimer’s disease
Phase 3 Early 2018
Phase 3 initiated 2Q 2015. Part A enrollment completed September 2016. Part B enrollment completion announced June 1, 2017. Data from Part A due early 2018. Part B due late 2018.
ZFGN
$3.71
-0.02  (-0.54%)
ZGN-1061
Diabetes
Phase 2 Early 2018
Phase 2 initiation due 3Q 2017. Update due early 2018.
THERF
$5.72
+0.31  (+5.73%)
Ibalizumab
Multi-drug resistant HIV-1
PDUFA
Original PDUFA date January 3, 2018 extended 3 months to April 3. 2018.
LLY
$84.09
+0.91  (+1.09%)
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
PDUFA priority review
Phase 3 interim analysis April 24, 2017 met primary endpoint. Priority review granted October 12, 2017. PDUFA date not announced - estimate April 12, 2017 using 6-month timeline.
RARE
$47.83
-0.01  (-0.04%)
KRN23 Burosumab
X-Linked Hypophosphatemia (XLH)
PDUFA priority review
Phase 3 data released April 18, 2017 - primary endpoint met. PDUFA date under priority review April 17, 2018. Advisory Committee Meeting not expected.
RIGL
$3.90
+0.06  (+1.56%)
Fostamatinib
Immune Thrombocytopenic Purpura (ITP)
PDUFA
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. PDUFA date April 17, 2018. Noted October 2, 2017 that no Advisory Committee meeting is planned.
ABBV
$95.19
+1.59  (+1.69%)
Elagolix
Endometriosis
PDUFA priority review
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing announced September 6, 2017. Priority review announced October 27, 2017. Exact PDUFA date not announced. Estimate April 27, 2017 based on 6-month review.
NBIX
$72.37
+0.6  (+0.83%)
Elagolix
Endometriosis
PDUFA priority review
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing announced September 6, 2017. Priority review announced October 27, 2017. Exact PDUFA date not announced. Estimate April 27, 2017 based on 6-month review.
ALKS
$48.05
+0.28  (+0.57%)
ALKS 3831 - ENLIGHTEN-2
Schizophrenia
Phase 3 Fall 2018
Pivotal trial initiated February 2016. Data due fall of 2018.
AMGN
$169.96
+1.17  (+0.69%)
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
PDUFA
Phase 3 trial met PFS endpoint - March 2015. Announced February 28, 2017 that interim analysis met secondary endpoint of overall survival (OS). PDUFA date for sNDA April 30, 2018.
KPTI
$11.11
-0.01  (-0.05%)
Selinexor - STORM
Quadruple Refractory Multiple Myeloma
Phase 2b April 2018
Phase 2b STORM Study Expansion data due April 2018.
NBRV
$6.13
+0.03  (+0.49%)
Lefamulin - LEAP 2
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
Phase 3 Spring 2018
Phase 3 data due spring 2018.
AMGN
$169.96
+1.17  (+0.69%)
Erenumab
Migraine
PDUFA
Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
NVS
$84.42
+1.2  (+1.44%)
Erenumab
Migraine
PDUFA
Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
REPH
$9.59
+0.45  (+4.87%)
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery
PDUFA
Phase 3 data from second trial released November 28, 2016. Primary endpoint met. NDA filing announced July 31, 2017. PDUFA date May 26, 2018.
AMGN
$169.96
+1.17  (+0.69%)
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
PDUFA
PDUFA date for sBLA filing May 28, 2017.
KTOV
$2.18
+0.21  (+10.65%)
KIT-302
Osteoarthritis and Hypertension
PDUFA
PDUFA date May 31, 2018.
VRX
$15.80
+0.23  (+1.44%)
IDP-118
Psoriasis
PDUFA
PDUFA date June 18, 2018.
ABBV
$95.19
+1.59  (+1.69%)
Elagolix
Uterine Fibroids
Phase 3 2018
Phase 3 initiated January 2016. Data due 2018.
ABBV
$95.19
+1.59  (+1.69%)
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2 2Q 2018
Phase 2 pivotal data 2Q 2018.
ACRS
$23.04
+0.22  (+0.96%)
ATI-50002
Patchy alopecia areata
Phase 2 1H 2018
Phase 2 trial to be initiated October 2017. Data due 1H 2018.
AGN
$170.40
-0.72  (-0.43%)
ATOGEPANT
Prophylaxis (migraine)
Phase 2b
Phase 2b top-line data due 1H 2018.
AGN
$170.40
-0.72  (-0.43%)
UBROGEPANT
Acute (migraine)
Phase 3
Phase 3 initiated July 2016. Data due 1H 2018.
AGN
$170.40
-0.72  (-0.43%)
ESMYA (ulipristal acetate)
Uterine Fibroids
PDUFA 1H 2018
Phase 3 data released January 18, 2017 - endpoints met. PDUFA date 1H 2018 - exact date not provided.
ALRN
$11.94
-0.34  (-2.77%)
ALRN-6924
Peripheral T-cell lymphoma (PTCL)
Phase 2a 1H 2018
Phase 2a interim data due 1H 2018.
AMGN
$169.96
+1.17  (+0.69%)
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
Phase 3
Phase 3 enrolling. Estimate data 1H 2018 using clinicaltrials.gov data.
ANAB
$77.54
+2.27  (+3.02%)
ANB020
Severe adult eosinophilic asthma
Phase 2a
Phase 2a data due 2Q 2018.
ANIK
$54.13
+0.16  (+0.29%)
Cingal
Osteoarthritis
Phase 3 1H 2018
Phase 3 completion of enrollment announced October 25, 2017. Trial to be completed 1H 2018.
ARGS
$0.20
+0  (+0.25%)
rocapuldencel-T (AGS-003) ADAPT Trial
Metastatic renal cell carcinoma (mRCC)
Phase 3 1H 2018
Phase 3 trial recommended be discontinued for futility - February 22, 2016. Noted August 9, 2017 that it intends to continue the ADAPT trial until at least the pre-specified number of 290 events occurs. Noted further on November 9, 2017 that it intends to request to the FDA to increase the number beyond 290. Interim analysis 1H 2018.
ARRY
$11.28
+0  (+0%)
Binimetinib - COLUMBUS
BRAF mutant melanoma cancer
PDUFA
Phase 3 data released September 26, 2016 met primary endpoint. PDUFA date June 30, 2018 - no Adcom anticipated.
AVIR
$0.58
+0.01  (+1.75%)
BTA074 5% topical gel
Condyloma
Phase 2 2Q 2018
Phase 2 data due 2Q 2018.
AXSM
$4.71
+0.11  (+2.39%)
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 1H 2018
Phase 3 initiated March 2016. Top-line data due 1H 2018.
AZN
$33.87
+0.49  (+1.47%)
Selumetinib - ASTRA
Thyroid cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$33.87
+0.49  (+1.47%)
PT010
Chronic obstructive pulmonary disease (COPD)
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$33.87
+0.49  (+1.47%)
Lynparza
First-line ovarian cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$33.87
+0.49  (+1.47%)
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3
Phase 3 data released July 27, 2017 - primary endpoint not met. Overall survival data due 1H 2018.
AZN
$33.87
+0.49  (+1.47%)
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$33.87
+0.49  (+1.47%)
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$33.87
+0.49  (+1.47%)
Durvalumab +/- tremelimumab (ARCTIC)
Lung cancer
Phase 3 1H 2018
Phase 3 data 1H 2018.
BHVN
$25.60
+0.52  (+2.07%)
Rimegepant
Migraine
Phase 3
Phase 3 trial initiation announced July 24, 2017 with top-line data due 1H 2018.
BMY
$61.69
+0.89  (+1.45%)
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3
Phase 3 data due 1H 2018.
BMY
$61.69
+0.89  (+1.45%)
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3
Phase 3 data due 1H 2018.
BMY
$61.69
+0.89  (+1.45%)
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3
Phase 3 data due 1H 2018.
BMY
$61.69
+0.89  (+1.45%)
CM-078 – Opdivo
Second-line Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3 data due 1H 2018.
BMY
$61.69
+0.89  (+1.45%)
CM-548 - Opdivo+SOC
First-line Glioblastoma (GBM) cancer
Phase 2
Phase 2 data due 1H 2018.
BOLD
$28.46
+1  (+3.64%)
AT342 - VALENS
Crigler-Najjar
Phase 1/2 2Q 2018
Phase 1/2 preliminary data due 2Q 2018.
CLDX
$2.82
-0.04  (-1.41%)
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2b 2Q 2018
Phase 2b completion of enrollment announced August 23, 2017. Data 2Q 2018.
CLSD
$6.94
-0.06  (-0.86%)
Suprachoroidal CLS-TA - TYBEE
Diabetic Macula Edema (DME)
Phase 2 2Q 2018
Phase 2 completion of enrollment announced October 24, 2017 with preliminary data 2Q 2018.
CLSD
$6.94
-0.06  (-0.86%)
Suprachoroidal CLS-TA - HULK
Diabetic macular edema (DME)
Phase 1/2 2Q 2018
Phase 1/2 enrollment completion announced April 20, 2017. Preliminary data due 2Q 2018.
CNAT
$4.05
-0.03  (-0.74%)
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2b 1H 2018
Phase 2b initiated May 2014. Topline data due 1H 2018.
CORI
$11.67
+0.72  (+6.57%)
Corplex Donepezil
Alzheimer's disease
Phase 3 1H 2018
Pilot bioequivalence data due released May 11, 2017. Pivotal trial commenced fall of 2017 with preliminary data due 1H 2018.
CPRX
$3.22
+0.15  (+5.06%)
Firdapse
Congenital Myasthenic Syndromes (CMS)
Phase 3 1H 2018
Phase 3 data due 1H 2018.
CTIC
$2.87
+0.05  (+1.77%)
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 3
Phase 3 data due 1H 2018. Noted August 2, 2017 that enrollment has completed.
DBVT
$24.31
-1.69  (-6.51%)
Viaskin Milk
Cow’s milk protein allergy (CMPA)
Phase 2b 1H 2018
Phase 2b data due 1H 2018.
ESPR
$56.67
+3.5  (+6.59%)
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due 2Q and 3Q 2018.
ESPR
$56.67
+3.5  (+6.59%)
Bempedoic acid (ETC-1002-040) - Clear Harmony
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 3
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
EXEL
$26.06
+0.41  (+1.59%)
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 3 1H 2018
Phase 3 enrollment completed 1Q 2017. Data due 1H 2018.
EYEG
$1.10
+0.01  (+0.91%)
EGP-437
Non-infectious anterior uveitis
Phase 3 2Q 2018
Phase 3 top-line data due 2Q 2018.
FBIO
$3.99
+0.02  (+0.5%)
CEVA101
Severe Traumatic Brain Injury
Phase 2
Phase 2 data in children due 1H 2018.
FBIO
$3.99
+0.02  (+0.5%)
Pepvax vaccine
Cytomegalovirus (CMV)
Phase 2
Phase 2 data due 1H 2018.
FBIO
$3.99
+0.02  (+0.5%)
IV Tramadol
Post-operative Pain
Phase 3 2Q 2018
Phase 3 initiation announced September 27, 2017 with data due 2Q 2018.
FLKS
$4.03
+0.03  (+0.75%)
FLX-787
Amyotrophic lateral sclerosis (ALS)
Phase 2
Phase 2 initiated September 2016. Readout due 2017/18.
GEMP
$9.50
+0.02  (+0.21%)
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
Phase 2b 2Q 2018
Phase 2b data due 2Q 2018.
GILD
$72.26
+0.13  (+0.18%)
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2 2Q 2018
Phase 2 initiation announced April 4, 2017. Trial to be completed 2Q 2018.
GILD
$72.26
+0.13  (+0.18%)
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 2Q 2018
Phase 2 trial to be completed 2Q 2018.
GLMD
$8.05
-0.08  (-1.04%)
Aramchol - ARREST
Non-Alcoholic Steatohepatitis (NASH)
Phase 2b 2Q 2018
Phase 2b data due 2Q 2018.
GLPG
$92.99
-0.4  (-0.43%)
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2 2Q 2018
Phase 2 initiation announced April 4, 2017. Trial to be completed 2Q 2018.
GLPG
$92.99
-0.4  (-0.43%)
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2 2Q 2018
Phase 2 initiation announced April 4, 2017. Trial to be completed 2Q 2018.
GTHX
$20.27
+0.3  (+1.5%)
G1T38 plus Faslodex
ER+ breast cancer
Phase 1b 2Q 2018
Phase 1b preliminary data due 2Q 2018.
IDRA
$2.30
+0.12  (+5.76%)
IMO-8400
Dermatomyositis
Phase 2 2Q 2018
Phase 2 initiated November 2015. Enrollment to be completed by the end of 2017 with data due 2Q 2018.
INCY
$98.28
-0.67  (-0.68%)
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 3 1H 2018
Phase 3 initiated June 2016. Initial data due 1H 2018.
INCY
$98.28
-0.67  (-0.68%)
Ruxolitinib - REACH 1
Graft versus host disease
Phase 3 1H 2018
Phase 2 pivotal trial dosing initiation announced December 30, 2016. Data due 1H 2018.
JNCE
$14.94
-0.1  (-0.67%)
JTX-2011
Solid tumors - Cancer
Phase 1/2
Phase 1/2 trial initiated September 2017.Phase 2 arm initiation announced April 21, 2017. Efficacy data due 1H 2018.
JNJ
$139.23
+1.3  (+0.94%)
Esketamine
Treatment resistant depression
Phase 3
Phase 3 ongoing. Data and regulatory filings likely due 2018.
KURA
$15.65
+0.2  (+1.29%)
Tipifarnib
Lower risk myelodysplastic syndromes (MDS) - cancer
Phase 2
Phase 2 top-line data due 1H 2018.
MACK
$11.88
-0.3  (-2.47%)
MM-141 - CARRIE
Cancer - front line pancreatic cancer
Phase 2
Phase 2 completion of enrollment announced June 19, 2017. Data due 1H 2018.
MDWD
$4.80
+0  (+0%)
NexoBrid
Severe burns
Phase 3
Phase 3 initiated mid April 2015. Data due 1H 2018.
MEIP
$2.16
+0.03  (+1.4%)
Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
Phase 2 1H 2018
Phase 2 commencement of dosing announced June 14, 2017 - data from first stage due 1H 2018.
MGNX
$20.14
+0.44  (+2.23%)
Margetuximab in combination with pembrolizumab
Gastric cancer
Phase 2 1H 2018
Phase 2 data due 1H 2018.
MTNB
$1.20
+0.01  (+0.84%)
MAT2501
Non-tuberculous mycobacterium (NTM)
Phase 2
Phase 2 trial to be initiated 2H 2018. Data from PK/tolerability trial due 2Q 2018.
NBIX
$72.37
+0.6  (+0.83%)
Elagolix
Uterine Fibroids
Phase 3 2018
Phase 3 initiated by partner Abbvie in January 2016. Data due 2018.
PBYI
$104.85
+0.8  (+0.76%)
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
PFNX
$2.83
+0.04  (+1.43%)
PF708 and Forteo
Osteoporosis
Phase 3 1H 2018
Top-line immunogenicity data due 1H 2018.
PRTA
$46.00
+1.4  (+3.13%)
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
Phase 2b 2Q 2018
Phase 2b data due 2Q 2018.
PSTI
$1.48
+0.02  (+1.36%)
PLX-PAD (stem cells)
Intermittent claudication, or IC
Phase 2 1H 2018
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due 1H 2018.
RNN
$2.13
+0.01  (+0.71%)
RX-3117 in combination with Abraxane
First-line pancreatic cancer
Phase 2a
Phase 2 data due 2Q 2018.
RXDX
$16.25
+0.5  (+3.17%)
RXDX-105
Solid tumors - cancer
Phase 1b 1H 2018
Phase 1b data update 1H 2018.
RYTM
$26.98
-0.02  (-0.08%)
Setmelanotide
POMC Epigenetic Disorders
Phase 2 1H 2018
Phase 2 data due 1H 2018.
RYTM
$26.98
-0.02  (-0.08%)
Setmelanotide
Alstrom Syndrome
Phase 2 1H 2018
Phase 2 data due 1H 2018.
RYTM
$26.98
-0.02  (-0.08%)
Setmelanotide
POMC Heterozygous Deficiency Obesity
Phase 2 1H 2018
Phase 2 data due 1H 2018.
SBBP
$6.30
+0.35  (+5.88%)
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome
Phase 3 2Q 2018
Phase 3 completion of enrollment announced June 27, 2017 with top-line data due 2Q 2018.
SGMO
$15.10
+0.4  (+2.72%)
SB-318
MPS Type 1
Phase 1/2 1H 2018
Phase 1/2 data due 1H 2018.
SGMO
$15.10
+0.4  (+2.72%)
SB-FIX
Hemophilia B
Phase 1/2 1H 2018
Phase 1/2 data due 1H 2018.
SGMO
$15.10
+0.4  (+2.72%)
SB-913 - CHAMPIONS
MPS Type 2
Phase 1/2 1H 2018
Phase 1/2 commencement of dosing announced November 15, 2017 with data due 1H 2018.
SNDX
$8.43
-0.09  (-1.06%)
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC)
Phase 1/2 1H 2018
Phase 2 trial to advance to second stage of trial - noted May 16, 2017. Updated data due 1H 2018.
SNDX
$8.43
-0.09  (-1.06%)
E2112
HR+, HER2- breast cancer
Phase 3 1H 2018
Phase 3 PFS data due by the end of 1H 2018.
SNGX
$2.24
+0  (+0%)
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Phase 3
Phase 3 data due 1H 2018.
SVRA
$11.96
+0.52  (+4.54%)
Aironite - INDIE
Pulmonary hypertension (PH)
Phase 2 1H 2018.
Phase 2 completion of enrollment announced October 18, 2017. Data due 1H 2018.
TBPH
$28.16
-0.42  (-1.47%)
TD-9855
nOH
Phase 2a 1H 2018
Phase 2a data due 1H 2018.
TCON
$2.60
-0.05  (-1.89%)
TRC253
Prostate cancer
Phase 1/2 1H 2018
Phase 1/2 dosing commenced May 24, 2017. Completion of dose escalation phase due 1H 2018.
TCON
$2.60
-0.05  (-1.89%)
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 1H 2018
Phase 2 dosing initiated May 2016 with data due 1H 2018.
TGTX
$7.58
-0.12  (-1.63%)
TG-1101 and TGR-1202 - UNITY-CLL study
Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)
Phase 3 2Q 2018
Phase 3 completion of full enrollment announced October 16, 2017 with top-line data due 2Q 2018.
TNXP
$3.79
+0.11  (+2.98%)
TNX-102 SL
Post-traumatic stress disorder (PTSD)
Phase 3 1H 2018
Initiation of first of two Phase 3 trials announced March 28, 2017 in military-related PTSD 1Q 2017. Interim analysis due 1H 2018 with top-line data due 2H 2018.
TOCA
$10.12
-0.06  (-0.59%)
Toca 511 & Toca FC
Recurrent brain cancer
Phase 2/3
Data from Phase 2 portion are due 1H 2018.
TSRO
$86.01
+2.47  (+2.95%)
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 1H 2018
Phase 1/2 enrolling. Initial data presented at ASCO investor event. ORR 4/13 patients. Further data due 1H 2018.
URGN
$41.00
-0.8  (-1.92%)
MitoGel - OLYMPUS
Upper tract urothelial carcinoma (UTUC)
Phase 3 2Q 2018
Phase 3 enrollment commenced April 3, 2017. Top-line data due 2Q 2018.
VICL
$1.97
-0.01  (-0.51%)
VCL-HB01 HSV-2 Therapeutic Vaccine
Genital Herpes in Adults
Phase 2 2Q 2018
Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018.
VKTX
$2.82
+0.05  (+1.8%)
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 1H 2018
Phase 2 trial to be completed 1H 2018.
VTGN
$0.89
-0.03  (-3.24%)
AV-101
Monotherapy Treatment Major Depressive Disorder
Phase 2 1H 2018
Phase 2 top-line data due 1H 2018.
ZGNX
$37.90
+1.7  (+4.69%)
ZX008 - Study 1504
Dravet syndrom
Phase 3 2Q 2018
Phase 3 data due 2Q 2018.
ALNY
$129.93
+1.78  (+1.38%)
Givosiran
Acute hepatic porphyrias
Phase 3 Mid-2018
Phase 3 trial initation announced November 7, 2017 with interim analysis data available in mid-2018.
BYSI
$34.05
+0  (+0%)
Plinabulin (Trial 106)
Prevention of neutropenia
Phase 2/3 Mid-2018
First data due mid-2018.
CELG
$105.47
+2.31  (+2.24%)
Luspatercept - BELIEVE
b -thalassemia
Phase 3
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
CELG
$105.47
+2.31  (+2.24%)
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 Mid-2018
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
EBIO
$0.66
-0.03  (-3.64%)
Vicinium
Non-muscle invasive bladder cancer (NMIBC)
Phase 3 Mid-2018
Phase 3 top-line data (3-month) due mid-2018 and 12-month data due 2Q 2019.
FOMX
$5.51
+0.05  (+0.91%)
FMX103
Papulopustular rosacea
Phase 3 Mid-2018
Phase 2 top-line data released September 12, 2016. Endpoints met. Phase 3 top-line data due mid-2018.
FOMX
$5.51
+0.05  (+0.91%)
FMX101 - FX2017-22
Acne
Phase 3 Mid-2018
Phase 3 data released March 27, 2017 - three of four primary endpoints met across two trials. Third Phase 3 trial data due mid-2018.
GNMX
$1.36
+0.03  (+2.26%)
AEVI-001 (NFC-1)
ADHD - 9-Gene subset
Phase 2 Mid-2018
Phase 2 data due mid-2018.
GNMX
$1.36
+0.03  (+2.26%)
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2 Mid-2018
Phase 1/2 data due mid-2018.
LLY
$84.09
+0.91  (+1.09%)
Ramucirumab
Second-line bladder cancer
Phase 3
Phase 3 PFS data released May 31, 2017 - primary endpoint met. Final OS results are currently expected in mid-2018.
MRTX
$17.85
-0.4  (-2.2%)
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
Phase 2 Mid-2018
Phase 2 data due by mid-2018.
OBSV
$10.65
-0.1  (-0.94%)
OBE2109 - EDELWEISS
Endometriosis
Phase 2b Mid-2018
Phase 2b data due mid-2018.
RDHL
$5.23
+0.02  (+0.38%)
RHB-104 MAP US
Crohn’s disease
Phase 3 Mid-2018
Phase 3 enrollment completion announced November 9, 2017 with data due mid-2018.
RGLS
$0.90
-0  (-0.39%)
RG-012 - HERA
Alport Syndrome
Phase 2
Phase 2 interim data due mid-2018.
SCYX
$1.91
-0.03  (-1.55%)
SCY-078 - oral
Vulvovaginal candidiasis (VVC)
Phase 2 Mid-2018
Phase 2 initiation of dosing announced August 3, 2017 - data due mid-2018.
SNSS
$3.03
+0.16  (+5.57%)
SNS-062
Advanced B-Cell Malignancies
Phase 1/2 Mid-2018
Phase 1/2 initiation of dosing announced July 18, 2017. Interim data due mid-2018.
VNDA
$13.10
+0.05  (+0.38%)
Tradipitant
Gastroparesis
Phase 2 Mid-2018
Phase 2 data due mid-2018.
XLRN
$37.44
+0  (+0%)
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 Mid-2018
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
XLRN
$37.44
+0  (+0%)
Luspatercept - BELIEVE
b -thalassemia
Phase 3 Mid-2018
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
AKCA
$18.41
+0.28  (+1.54%)
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
PDUFA
PDUFA date August 30, 2017.
ALXN
$108.61
+0.12  (+0.11%)
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3 Mid-2018
Phase 3 enrollment to be completed in 2017 with data due mid-2018.
BLRX
$1.04
-0.01  (-0.96%)
BL-8040
Stem-cell mobilization for allogeneic transplantation
Phase 2 Mid-2018
Phase 2 top-line data due by mid-2018.
ONCS
$2.00
-0.1  (-4.77%)
ImmunoPulse IL-12 - PISCES
Melanoma - cancer
Phase 2b Mid-2018
Phase 2b data due mid-2018.
AGTC
$3.90
+0.1  (+2.63%)
rAAV-hRS1
X-linked retinoschisis (XLRS)
Phase 1/2
Phase 1/2 completion of enrollment due 1Q 2018 with data due after the last patient has been followed for six months (est 3Q 2018).
AMRN
$3.28
-0.01  (-0.46%)
Vascepa REDUCE-IT outcomes trial
High Triglycerides With Mixed Dyslipidemia
3Q 2018
Interim analysis announced September 12, 2016 - trial to proceed. Second interim analysis August 14, 2017 also recommended trial to continue. Final data due 3Q 2018.
AQXP
$10.56
-0.01  (-0.1%)
AQX-1125 LEADERSHIP
Bladder pain syndrome/interstitial cystitis (BPS/IC).
Phase 3
Phase 2 trial did not meet endpoints - June 2015 but postive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Data due 3Q 2018.
FLKS
$4.03
+0.03  (+0.75%)
FLX-787 - COMMEND US trial
Amyotrophic lateral sclerosis (ALS)
Phase 2 3Q 2018
Phase 2 start noted August 1, 2017. Data due 3Q 2018.
GILD
$72.26
+0.13  (+0.18%)
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 3 3Q 2018
Phase 3 trial to be completed 3Q 2018.
HSGX
$2.03
+0.04  (+2.01%)
NeoCart
Cartilage defects in the knee
Phase 3
Phase 3 completion of enrollment announced June 27, 2017. Top-line data and potential BLA filing 3Q 2018.
VTL
$5.03
-0.03  (-0.5%)
VTI-308
Alcohol-induced liver decompensation, or AILD
Phase 3 3Q 2018
Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due 3Q 2018.
CNCE
$22.28
+1.03  (+4.84%)
AVP-786
Agitation in patients with Alzheimer's disease
Phase 3
Phase 3 initiated December 2015. Trial to be completed 3Q 2018
ABBV
$95.19
+1.59  (+1.69%)
ABT-494 - SELECT-COMPARE
Rheumatoid arthritis
Phase 3 2018
Phase 3 data due 2018.
ABBV
$95.19
+1.59  (+1.69%)
Imbruvica - PHOENIX
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 2018
Phase 3 data possibly due 2018.
ABUS
$5.85
+0.15  (+2.63%)
ARB-1467, tenofovir, and pegylated interferon
Hepatitis B (HBV)
Phase 2 2H 2018
Phase 2 interim data due 2H 2018 with full data due 2019.
ACIU
$11.17
+0.8  (+7.71%)
ACI-24 (anti-Abeta vaccine)
Alzheimer's disease-like characteristics in individuals with Down syndrome
Phase 1/2 2018
Phase 1/2 completion of recruitment of low-dose cohort noted September 12, 2017. Interim data due 2018.
ACRS
$23.04
+0.22  (+0.96%)
ATI-50001
Alopecia totalis and alopecia universalis
Phase 2 YE 2018
Phase 2 data due by the end of 2018.
ACRS
$23.04
+0.22  (+0.96%)
A-101
Common warts (verruca vulgaris)
Phase 2b 2H 2018
Phase 2 data released August 2016. Phase 2b trial initiation announced June 29, 2017. Top-line data due 2H 2018.
ADVM
$3.00
+0.05  (+1.69%)
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 1/2 2H 2018
Phase 1/2 preliminary data due 2H 2018.
ADXS
$3.08
+0  (+0%)
ADXS-PSA and Keytruda
Castrate-resistant prostate cancer
Phase 1/2 2018
Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Preliminary data due 2018.
AGLE
$4.45
-0.04  (-0.9%)
AEB1102
Arginase I deficiency
Phase 1/2
Phase 1/2 dosing in repeat dose part (Part 2) announced September 6, 2017. Top-line data due 2H 2018.
AGN
$170.40
-0.72  (-0.43%)
Brazikumab
Crohn's disease
Phase 2b
Phase 2b data due 2018.
AGN
$170.40
-0.72  (-0.43%)
Cariprazine
Major depressive disorder (MDD)
Phase 3
Phase 3 data due 2H 2018.
AGN
$170.40
-0.72  (-0.43%)
ABICIPAR
Age-related macular degeneration (AMD)
Phase 3
Phase 3 data due 2H 2018.
AKBA
$15.74
+0.25  (+1.61%)
Vadadustat - TRILO2GY
Three-times-weekly dosing regimen for vadadustat
Phase 3 YE 2018
Phase 3 trial to be initiated late 2017 or early 2018 with data due by the end of 2018.
AKBA
$15.74
+0.25  (+1.61%)
Vadadustat - FO2RWARD
Renal anemia
Phase 2
Phase 2 data due by the end of 2018.
AKCA
$18.41
+0.28  (+1.54%)
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 2b 2018
Phase 2b initiation announced March 30, 2017. Data due 2018.
ALDX
$6.30
+0.05  (+0.8%)
ADX-102
Allergic conjunctivitis
Phase 2b 2H 2018
Phase 2b data released June 14 2017 - primary endpoint not met. However, Phase 3 trial is planned for 1H 2018 with data due 2H 2018.
ALDX
$6.30
+0.05  (+0.8%)
ADX-102
Noninfectious anterior uveitis
Phase 3 2H 2018
Phase 3 trial initiation announced April 27, 2017 with data due 2H 2018.
ALDX
$6.30
+0.05  (+0.8%)
ADX-102
Sjögren-Larsson Syndrome (SLS)
Phase 2 2H 2018
Phase 3 trial to be initiated 1H 2018 with initial data due 2H 2018.
ALNY
$129.93
+1.78  (+1.38%)
ALN-CC5 (cemdisiran)
Atypical hemolytic-uremic syndrome (aHUS)
Phase 1/2 2018
Phase 2 trial initiation announced September 26, 2017 with initial data due 2018.
ARGS
$0.20
+0  (+0.25%)
ARGX-113
Pemphigus vulgaris (PV)
Phase 2 2H 2018
Phase 2 initiation announced September 26, 2017 with interim data due 2H 2018.
ARGX
$24.60
+0.02  (+0.08%)
ARGX-113
Immune thrombocytopenia (ITP)
Phase 2 2H 2018
Phase 2 data due 2H 2018.
AUPH
$5.12
-0.01  (-0.2%)
Voclosporin
Dry eye syndrome
Phase 2 2H 2018
Phase 2 trial to be initiated 2Q 2018 with data due 2H 2018.
AUPH
$5.12
-0.01  (-0.2%)
Voclosporin
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
Phase 2 2H 2018
Phase 2 trial to be initiated 1H 2018. Interim data readouts are anticipated 2H 2018.
AZN
$33.87
+0.49  (+1.47%)
Farxiga - DECLARE
Type-2 diabetes
Phase 3 2H 2018
Cardiovascular outcome data due 2H 2018.
AZN
$33.87
+0.49  (+1.47%)
Benralizumab - TERRANOVA
COPD
Phase 3 2H 2018
Phase 3 data due 2H 2018.
AZN
$33.87
+0.49  (+1.47%)
Farxiga - DECLARE
Cardiovascular Outcomes
Phase 3
Phase 3 data due 2H 2018.
AZN
$33.87
+0.49  (+1.47%)
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 2H 2018
Phase 3 data due 2H 2018.
AZN
$33.87
+0.49  (+1.47%)
Anifrolumab
Lupus
Phase 3 2H 2018
Phase 3 data due 2H 2018.
BIIB
$309.11
-0.35  (-0.12%)
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
Phase 2 2018
Phase 2 initiated 2016. Data due in 2018.
BLPH
$1.46
-0.03  (-2.01%)
INOpulse delivery device
Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF)
Phase 2 YE 2018
Phase 2 initiated May 2016. Data presented at American Thoracic Society (ATS) Conference, May 21 2017. Phase 2b planned for early 2018 with data due late 2018.
BLPH
$1.46
-0.03  (-2.01%)
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 3
Phase 3 commenced enrollment June 2016. Interim analysis and top-line data due 2018.
BLRX
$1.04
-0.01  (-0.96%)
BL-8040
Consolidation treatment for AML cancer patients
Phase 2b
Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
BMY
$61.69
+0.89  (+1.45%)
CM-602 – Opdivo + Elo + SOC
Myeloma
Phase 3
Phase 3 data due 2H 2018. Noted September 6, 2017 that trial has been placed on partial hold.
BYSI
$34.05
+0  (+0%)
Plinabulin
Non small cell lung cancer - refractory
Phase 3 2018
Phase 3 trial initiated 2016. Interim data due 2018. Final data due 1Q 2019.
CELG
$105.47
+2.31  (+2.24%)
REVLIMID - ROBUST
First-line ABC Diffuse large B-cell lymphoma (DLBCL)
Phase 3 2018
Phase 3 data due 2018.
CELG
$105.47
+2.31  (+2.24%)
MM-007 OPTIMISMM
Multiple Myeloma - refractory
Phase 3 2018
Phase 3 data due 2018.
CELG
$105.47
+2.31  (+2.24%)
Oral Azacitidine - CC-486-AML-001
Post induction AML Maintenance
Phase 3 2018
Phase 3 data due 2018.
CELG
$105.47
+2.31  (+2.24%)
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
Phase 3 YE 2018
Phase 3 data due year end 2018.
CELG
$105.47
+2.31  (+2.24%)
ABRAXANE - IMpower 130 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3 2018
Phase 3 data due 2018.
CELG
$105.47
+2.31  (+2.24%)
ABRAXANE - IMpower 131 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3 2018
Phase 3 data due 2018.
CELG
$105.47
+2.31  (+2.24%)
ABRAXANE - IMPassion ( I/O Combo)
Triple Negative Metastatic Breast Cancer
Phase 3
Phase 3 data due 2018.
CFRX
$0.99
+0.02  (+2.06%)
CF-301
Serious infections caused byStaph aureus including MRSA
Phase 2 4Q 2018
Phase 2 initiation announced May 25, 2017 - data due 4Q 2018.
CNAT
$4.05
-0.03  (-0.74%)
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 2H 2018
Phase 2b initiated November 2016. Data due 2H 2018.
CNCE
$22.28
+1.03  (+4.84%)
CTP-543
Alopecia areata
Phase 2a 2H 2018
Phase 2 clinical hold placed May 17, 2017 lifted July 10, 2017. Trial completion due 2H 2018.
EARS
$0.85
+0.02  (+2.25%)
AM-111 ASSENT
Acute inner ear hearing loss
Phase 3
Phase 3 ASSENT data due 2H 2018.
EIGR
$11.00
+0.3  (+2.8%)
Exendin 9-39
Post-Bariatric Hypoglycemia (PBH)
Phase 2 4Q 2018
Phase 2 to be initiated 4Q 2017 with completion 4Q 2018.
EIGR
$11.00
+0.3  (+2.8%)
Ubenimex - ULTRA
Secondary lymphedema
Phase 2 4Q 2018
Phase 2 dosing commenced July 2016. Enrollment to be completed 4Q 2017. Trial completion 4Q 2018.
EPZM
$12.88
+0.07  (+0.58%)
Tazemetostat
Adult patients with mesothelioma characterized by BAP1 loss-of-function
Phase 2 2018
Phase 2 dosing commenced August 2016. Enrollment completed June 2017 with data due 2018.
ESPR
$56.67
+3.5  (+6.59%)
Bempedoic Acid/ Ezetimibe (1002FDC-053)
Hypercholesterolemia
Phase 3 4Q 2018
Phase 3 initiation announced November 6, 2017. Data due 4Q 2018.
FGEN
$48.55
+1  (+2.1%)
Roxadustat - ANDES
Anaemia
Phase 3 2018
Phase 3 data due 2018.
FLKS
$4.03
+0.03  (+0.75%)
FLX-787 (Aust)
Multiple Sclerosis
Phase 2 2018
Phase 2 data due 2018.
GEMP
$9.50
+0.02  (+0.21%)
Gemcabene - AZURE-1
Nonalcoholic steatohepatitis (NASH) / Nonalcoholic fatty liver disease (NAFLD)
Phase 2 2H 2018
Phase 2 trial to be initiated in 4Q 2017 with data due 2H 2018.
GILD
$72.26
+0.13  (+0.18%)
GS-9876
Phase 2 2H 2018
Phase 2 trial to be completed 2H 2018.
GILD
$72.26
+0.13  (+0.18%)
GS-5734
Ebola
Phase 2 2H 2018
Phase 2 trial to be completed 2H 2018.
GILD
$72.26
+0.13  (+0.18%)
Axicabtagene ciloleucel - KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2
Phase 2 pivotal initiated November 2015. Data due 2018.
GILD
$72.26
+0.13  (+0.18%)
Axicabtagene ciloleucel - KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 1/2
Phase 1 data released at ASCO June 5, 2017. Complete remission 73%. Phase 2 data due 2018.
GILD
$72.26
+0.13  (+0.18%)
Axicabtagene ciloleucel - KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
Phase 1/2
Phase 2 data due 2018.
GSK
$35.02
-0.1  (-0.29%)
Closed Triple - CAPTAIN
Asthma
Phase 3
Phase 3 data due 2H 2018.
GTXI
$11.93
+0.81  (+7.28%)
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)
Phase 2 YE 2018
Phase 2 data due by the end of 2018.
GWPH
$127.46
+12.69  (+11.05%)
Epidiolex
Tuberous Sclerosis Complex
Phase 3
Phase 3 data due 2018.
HALO
$18.94
+0.24  (+1.28%)
PEGPH20 - HALO-301
Pancreatic cancer
Phase 3 Late 2018
Phase 3 dosing initiated March 2016. PFS data potentially due late 2018.
IMGN
$5.65
-0.05  (-0.84%)
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
Phase 3
Phase 3 data due in 2018.
IMRN
$5.33
-0.13  (-2.38%)
IMM-529
C. difficile infection
Phase 1/2
Phase 1/2 trial enrollment to commence mid-September 2017 with data due 4Q 2018.
INVA
$13.27
+0.1  (+0.72%)
Closed Triple
Asthma
Phase 3
Phase 3 data due 2H 2018.
IOVA
$8.55
+0.25  (+3.01%)
LN-145
Cervical cancer
Phase 2
Phase 2 dosing has commenced - noted August 16, 2017. Initial data due 2018.
JNJ
$139.23
+1.3  (+0.94%)
STELARA (USTEKINUMAB)
Ulcerative colitis
Phase 3
Phase 3 trial to be completed in 2018.
JNJ
$139.23
+1.3  (+0.94%)
DARZALEX (Daratumumab)
Frontline multiple myeloma (non-transplant)
Phase 3
Phase 3 data likely due 2018.
KPTI
$11.11
-0.01  (-0.05%)
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2b 2H 2018
Phase 2b additional interim data released June 23, 2017 at EHA. Final top-line data due 2H 2018.
MACK
$11.88
-0.3  (-2.47%)
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Phase 2
Phase 2 initiated mid Feb 2015. Data due 2H 2018.
MBRX
$1.65
+0.01  (+0.92%)
Annamycin
Acute myeloid leukemia (AML) - cancer
Phase 1/2
Phase 1/2 data due 2018.
MRK
$54.68
+0.57  (+1.07%)
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 3
Phase 3 initiated June 2016. Initial data due 2018.
MRNS
$6.39
+0.08  (+1.26%)
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 2018
Phase 2 data due 2018.
NBIX
$72.37
+0.6  (+0.83%)
INGREZZA - T-Force GOLD
Tourette syndrome - juvenile
Phase 2b Late-2018
Phase 2 data released May 23 - primary endpoint not met. Phase 2b trial initiation announced October 25, 2017. Top-line data due late 2018.
NVCR
$18.85
+0.7  (+3.85%)
Tumor Treating Fields (TTFields) STELLAR
Mesothelioma
Phase 2 2018
Phase 2 enrollment completion announced March 31, 2017. Data due 2018.
NVS
$84.42
+1.2  (+1.44%)
QVM149
Asthma
Phase 3
Phase 3 data due 2018.
NVS
$84.42
+1.2  (+1.44%)
Entresto - PIONEER
In-hospital initiation vs. enalapril following ADHF (acute decompensated heart failure)
Phase 3
Phase 3 trial completion due 2018.
NVS
$84.42
+1.2  (+1.44%)
Entresto - PARAGON
HF-pEF (heart failure with preserved ejection fraction)
Phase 3
Phase 3 interim analysis due 2018. Filing 2019.
NVS
$84.42
+1.2  (+1.44%)
AIN457 (Cosentyx)
Non-radiographic axial SpA
Phase 3
Phase 3 data due 2018.
OBSV
$10.65
-0.1  (-0.94%)
OBE022 - PROLONG
Pre-term labor
Phase 2a YE 2018
Phase 2a trial to be initiated late 2017 with data due late 2018.
OCUL
$4.47
-0.21  (-4.49%)
OTX-TP
Glaucoma and ocular hypertension
Phase 3 2H 2018
Phase 3 initiated October 2016. Data due 2H 2018.
PFE
$35.68
+0.33  (+0.93%)
Tanezumab
Cancer pain
Phase 3
Phase 3 ongoing. Estimate data due 2018 using clinicaltrials.gov data.
PLX
$0.71
-0  (-0.13%)
PRX-102
Fabry disease
Phase 3
Phase 3 dosing commenced October 2016. Enrollment to be completed 2H 2017 with data in 2018.
PRQR
$3.15
+0.05  (+1.61%)
QR-010
Genetic blindness
Phase 1/2 2018
Phase 1/2 commencement of dosing announced November 14, 2017. Interim safety and efficacy 6-month data due 2018, full 12 month data due 2019.
PULM
$1.57
-0.06  (-3.49%)
PUR1800
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Phase 2
Phase 2 trial to be initiated mid-2018 with data due late 2018.
RDHL
$5.23
+0.02  (+0.38%)
RHB-105 - ERADICATE Hp 2
H. pylori
Phase 3 2H 2018
Phase 3 final data released March 2016. Additional Phase 3 trial initiation announced June 15, 2017 with data due 2H 2018.
RETA
$24.92
+0.49  (+2%)
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
Phase 3 2H 2018
Phase 3 commenced enrollment October 2016 with data due 2H 2018.
RIGL
$3.90
+0.06  (+1.56%)
Fostamatinib
IgA nephropathy
Phase 2
Phase 2 preliminary data released January 5, 2017. Enrollment of second cohort to be completed in 2017 with data due in 2018.
SBBP
$6.30
+0.35  (+5.88%)
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
Phase 3 4Q 2018
Phase 3 top-line data expected in 4Q 2018.
SGEN
$59.67
+0.97  (+1.65%)
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Phase 3
Phase 3 enrollment completed November 2016. Data are due in 2018.
SNNA
$19.07
-0.16  (-0.86%)
SNA-001
Reduction of light-pigmented hair
Phase 3 2H 2018
Pivotal data due 2H 2018.
SNNA
$19.07
-0.16  (-0.86%)
SNA-001
Acne
Phase 3 2H 2018
Pivotal data due 2H 2018.
SVRA
$11.96
+0.52  (+4.54%)
Molgradex - IMPALA
Autoimmune pulmonary alveolar proteinosis (PAP)
Phase 3
Phase 3 data due by the end of 2018.
TBPH
$28.16
-0.42  (-1.47%)
Closed Triple - CAPTAIN
Asthma